Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.63 |
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | HRH1 | P35367 | 5/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2436215 | 0.98 | MAOB (0.61) | MAOBMAOASLC18A3SIGMAR1CYP3A4 | |
| SCHEMBL22545933 | 0.89 | MAOB (0.52) | MAOBMAOASLC18A3SIGMAR1KDM1A | |
| SCHEMBL31322216 | 0.82 | SLC18A3 (0.53) | MAOBMAOASLC18A3SIGMAR1HRH1 | |
| SCHEMBL3213057 | 0.81 | MAOA (0.58) | MAOBMAOACYP3A4CYP2D6HRH1 | |
| SCHEMBL324588 | 0.81 | MAOA (0.63) | MAOBMAOAKCNH2KDM1A | |
| SCHEMBL1681280 | 0.81 | MAOA (0.63) | MAOBMAOACYP3A4CYP2D6HRH1 | |
| SCHEMBL1638869 | 0.81 | MAOA (0.63) | MAOBMAOACYP3A4CYP2D6HRH1 | |
| SCHEMBL1639044 | 0.81 | MAOA (0.63) | MAOBMAOACYP3A4CYP2D6HRH1 | |
| SCHEMBL12015997 | 0.81 | MAOA (0.68) | MAOBMAOACYP3A4CYP2D6HRH1 | |
| SCHEMBL18897097 | 0.81 | MAOA (0.63) | MAOBMAOACYP3A4CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-117402124-A | Aryl sulfonamide compound and anti-influenza application thereof | 中国医学科学院医药生物技术研究所 | 2024-01-16 | — | — | CN | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| EP-3818053-B1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-3746432-B1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-12-14 | — | — | EP | disclosed |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-02-03 | — | — | US | disclosed |
| EP-2970119-B1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3890829-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007071598-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007024949-A3 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORP (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007024949-A2 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024949-A2 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| CN-1092412-A | Alkylenediamine derivatives | NIPPON CHEMIPHAR CO (JP) | 1994-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | MAOB 3276/4885MAOA 3420/4885SLC18A3 3512/4885 |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | MAOB 1257/4885MAOA 880/4885SLC18A3 357/4885 |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | MAOB 2489/4885MAOA 3312/4885SLC18A3 3641/4885 |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | MAOB 842/4885MAOA 874/4885SLC18A3 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.